27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ:BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.
- This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales.
- Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study.
- WM is a rare form of B-cell lymphoma that occurs in less than two percent of patients with non-Hodgkin lymphomas. Around 4,000 people are living with WM in the U.K.
- The NICE recommendation states that Brukinsa is considered cost-effective at a threshold of £20,000-30,000 per quality-adjusted life year.
- Also, the European Medicines Agency's Committee for Medicinal Products for Human Use backed Brukinsa approval for marginal zone lymphoma patients who have received at least one prior anti-CD20-based therapy.
- Price Action: BGNE shares closed lower by 1.45% at $154.82 on Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!